Kidney failure is a severe state of kidney disease in which kidney function falls below about 15% of normal. At this stage, patients typically require kidney replacement therapy such as hemodialysis, peritoneal dialysis, or kidney transplant.
Research in the United Kingdom found that preventing type 2 diabetes cut care-related greenhouse gas emissions by about 67%, while well-controlled disease was linked to 21% lower emissions than uncontrolled diabetes.
Bayer's Phase III FIND-CKD trial shows finerenone significantly slows kidney function decline in non-diabetic chronic kidney disease patients. The drug met its primary endpoint with improved eGFR slope over 32 months, marking its fifth consecutive positive Phase III trial. Bayer plans to submit the data to the FDA for label expansion into non-diabetic CKD.
New NICE guidance recommends offering SGLT-2 inhibitors earlier in type 2 diabetes treatment, potentially preventing 17,000 deaths over three years while saving the NHS £560 million through generic medicines.
New research demonstrates machine learning can optimize drug dosing, identifies biomarkers of treatment response, and validates prognostic criteria for long-term kidney survival in pediatric lupus nephritis patients.
New studies show SGLT2 inhibitors and GLP-1 receptor agonists reduce risks of kidney failure, cardiovascular events, and liver complications in patients with type 2 diabetes, with particularly strong benefits in those with cirrhosis.
Phase 3 trials demonstrate atrasentan slows kidney function decline in IgA nephropathy patients, while obinutuzumab achieves superior remission rates in primary membranous nephropathy compared to standard treatment.
Scientists in China report reversing Type 2 diabetes in a patient using stem cell therapy, while a separate study finds metformin may help women with diabetes live past 90. Both findings require larger trials.
The Phase III MAJESTY study met its primary endpoint, showing significantly more people achieved complete remission at two years with Gazyva versus tacrolimus. If approved, Gazyva would be the first therapy specifically indicated for primary membranous nephropathy.
Roche announced positive Phase III MAJESTY trial results showing Gazyva achieved significantly higher complete remission rates at two years versus tacrolimus in primary membranous nephropathy, with no new safety signals identified.
Roche announced that Gazyva/Gazyvaro met its primary endpoint in the Phase III MAJESTY study for primary membranous nephropathy, showing statistically significant complete remission rates versus tacrolimus. The drug could become the first approved therapy for this rare autoimmune kidney disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07492511 |
Renal and Hepatic Abnormal Doppler Patterns in Trauma |
RECRUITING | |
| NCT07484308 |
Application and Impact Assessment of Ultrasound Super-Resolution Blood Flow Imaging (URM) in Patients With Renal Failure |
COMPLETED | NA |
| NCT07446296 |
Kidney Transplant Improvement Through New Exercise Training to Increase Capacity |
RECRUITING | NA |
| NCT07419945 |
Older Kidney Patient Optimisation Pretransplant |
NOT_YET_RECRUITING | NA |
| NCT07377500 |
Dialysate Cooling for the Preservation of Cognitive Function in People Receiving Haemodialysis |
NOT_YET_RECRUITING | NA |
| NCT07369323 |
Erector Spinae Plane Block in Kidney Transplant Pain Management |
COMPLETED | NA |
| NCT07341516 |
Worldwide Assessment of Deceased Donor Kidney Utilization |
ENROLLING_BY_INVITATION | |
| NCT07160452 |
Levocarnitine for Reducing ESA Requirements in Hemodialysis Patients With Renal Anemia |
NOT_YET_RECRUITING | PHASE4 |
| NCT07053462 |
CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk |
RECRUITING | PHASE1/PHASE2 |
| NCT06972069 |
Tolerance Through Mixed Chimerism (Sip-Tego) |
RECRUITING | EARLY_PHASE1 |
